Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges

References

1. GonçalvesG.A.R. PaivaR.M.A. Gene therapy: advances, challenges and perspectives.Einstein (Sao Paulo)201715336937510.1590/s1679‑45082017rb402429091160
   [Google Scholar]
2. AspdenP. The costs and benefits of medical innovation.USNational Academies Press2002
   [Google Scholar]
3. LuR.M. HwangY.C. LiuI.J. Development of therapeutic antibodies for the treatment of diseases.J. Biomed. Sci.202027113010.1186/s12929‑019‑0592‑z31894001
   [Google Scholar]
4. AhluwaliaG. Available from: https://www.bdo.co.uk/en-gb/insights/industries/life-sciences/cell-and-gene-therapy-investing-in-a-new-tomorrow(Accessed on: 29 Dec 2023)
5. High-dose AAV gene therapy deaths.Nat. Biotechnol.202038891010.1038/s41587‑020‑0642‑932760031
   [Google Scholar]
6. MoodyJ. MilliganW.D. St OngeM. GoonewardeneA. RiversP. Cell and gene therapy: A snapshot of investor perspectives.Cytotherapy202123325626010.1016/j.jcyt.2020.11.00533281066
   [Google Scholar]
7. NorvielV. HoffmeisterD. RavitzG. RavitzJ. a preliminary evaluation of the RMAT designation's effect on publicly traded company stock priceAvailable from: https://www.wsgr.com/en/insights/a-preliminary-evaluation-of-the-rmat-designations-effect-on-publicly-traded-company-stock-price.html(Accessed on: 29 Dec 2023)
8. OhbaM. FalknerR. Innovative capabilities and strategic alliances: Who is gaining what in the pharmaceutical industry?J. Commer. Biotechnol.200713427328210.1057/palgrave.jcb.3050053
   [Google Scholar]
9. ParrishM. Pharma’s damaged reputation.Available from: https://www.pharmamanufacturing.com/sector/small-molecule/article/11303099/pharmas-damaged-reputation(Accessed on: 29 Dec 2023)
10. NeilJ. Important aspects of drug development.Available from: https://proventainternational.com/the-challenges-of-cmc-in-cell-and-gene-therapies/(Accessed on: 29 Dec 2023)
11. Management Sciences for Health. Pharmaceutical Financing Strategies2012Available from: https://msh.org/wp-content/uploads/2013/04/mds3-ch11-financing-strategies-mar2012.pdf(Accessed on: 29 Dec 2023)
12. HolianM. WhitneyM. GilbertA. How To navigate pharma collaboration and licensing agreements.Available from: https://www.lifescienceleader.com/doc/how-to-navigate-pharma-collaboration-and-licensing-agreements-0001(Accessed on: 29 Dec 2023)
13. CiuluR. Diversification strategy in the pharmaceutical industry.SSRN Electron J20082008128312910.2139/ssrn.1283129
    [Google Scholar]
14. FiricaC. Financial strategies and their impact on pharma companies’ budgetsAvailable from: https://www.linkedin.com/pulse/financial-strategies-impact-pharma-companies-budgets-firica-mba/(Accessed on: 29 Dec 2023)
15. ZhuJ. Key Considerations for your life sciences IP strategy.Available from: https://www.foxrothschild.com/publications/key-considerations-for-your-life-sciences-ip-strategy(Accessed on: 29 Dec 2023)
16. European commission. intellectual property. Available from: trade.ec.europa.eu (Accessed on: 29 Dec 2023). Available from:https://trade.ec.europa.eu/access-to-markets/en/content/intellectual-property(Accessed on: 29 Dec 2023)
17. RobinsonS. Chemistry, Manufscturing and controls (CMC), GARDP.Available from: https://revive.gardp.org/resource/chemistry-manufacturing-and-controls-cmc/?cf=encyclopaedia(Accessed on: 29 Dec 2023)